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original article
Use of hemoglobin A1C to 
detect Haitian-Americans with 
undiagnosed Type 2 diabetes
Utilização de hemoglobina A1C no rastreamento de haitianos 
americanos com diabetes tipo 2 não diagnosticado
Joel C. Exebio1, Gustavo G. Zarini1, Joan A. Vaccaro1, 
Cristobal Exebio2, Fatma G. Huffman1
ABSTRACT
Objective: To evaluate the validity of hemoglobin A1C (A1C) as a diagnostic tool for type 2 
diabetes and to determine the most appropriate A1C cutoff point for diagnosis in a sample of 
Haitian-Americans. Subjects and methods: Subjects (n = 128) were recruited from Miami-Dade 
and Broward counties, FL. Receiver operating characteristics (ROC) analysis was run in order 
to measure sensitivity and specificity of A1C for detecting diabetes at different cutoff points. 
Results: The area under the ROC curve was 0.86 using fasting plasma glucose ≥ 7.0 mmol/L as 
the gold standard. An A1C cutoff point of 6.26% had sensitivity of 80% and specificity of 74%, 
whereas an A1C cutoff point of 6.50% (recommended by the American Diabetes Association – 
ADA) had sensitivity of 73% and specificity of 89%. Conclusions: A1C is a reliable alternative to 
fasting plasma glucose in detecting diabetes in this sample of Haitian-Americans. A cutoff point 
of 6.26% was the optimum value to detect type 2 diabetes. Arq Bras Endocrinol Metab. 2012;56(7):449-55
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RESUMO
Objetivo: Avaliar a validade da hemoglobina A1C (A1C) como ferramenta para o diagnóstico 
de diabetes tipo 2 e determinar o ponto de corte mais apropriado para a A1C no diagnóstico de 
uma amostra de haitianos americanos. Sujeitos e métodos: Os sujeitos (n = 128) foram recruta-
dos dos condados de Miami-Dade e Broward na Flórida. A análise ROC (Receiver operating cha-
racteristics) foi feita de forma a medir a sensibilidade e especificidade de A1C para a detecção 
do diabetes em diferentes pontos de corte. Resultados: A área sob a curva ROC foi 0,86 usando 
a glicemia de jejum ≥ 7,0 mmol/L como padrão-ouro. O ponto de corte de 6,26% para a A1C 
apresentou sensibilidade de 80% e especificidade de 74%, enquanto o ponto de corte de 6,50% 
(recomendado pela American Diabetes Association – ADA) apresentou uma sensibilidade de 
73% e especificidade de 89%. Conclusões: A A1C foi uma alternativa confiável para a glicemia 
de jejum na detecção do diabetes nesta amostra de haitianos americanos. Um ponto de corte de 
6,26% foi o valor ótimo para a detecção do diabetes tipo 2.  Arq Bras Endocrinol Metab. 2012;56(7):449-55
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INTRODUCTION
Traditionally, the diagnosis of diabetes has been based on plasma glucose. Both fasting plasma glu-
cose (FPG) and oral glucose tolerance test (OGTT) have 
been widely used for more than three decades. However, 
both tests are inconvenient because they require fasting 
of at least 8 hours and, in the case of the OGTT, staying 
in the clinical facility for a long period of time. 
In recent years, several studies have examined the 
validity of hemoglobin A1C (A1C) as a diagnostic tool 
for type 2 diabetes (T2D) (1-4). A1C represents a mea-
sure of mean blood glucose during the two months 
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before the measurement, and does not require fasting 
or any special preparation. In 2009, an International 
Expert Committee recommended the use of A1C to 
diagnose diabetes with a cutoff point of ≥ 6.5% (5). In 
2010, the American Diabetes Association (ADA) adop-
ted this criterion (6). However, it was recognized that 
A1C levels may vary according to the ethnicity (7).
Data revealed that different ethnic groups show va-
riable sensitivity and specificity for A1C. Variations may 
be related to genetic differences in hemoglobin concen-
tration, glycation rates, and lifespan and number of red 
blood cells (8,9). When the recommended A1C cutoff 
point (≥ 6.5%) was tested in a sample representative of 
the general US population, sensitivity of A1C was lower 
compared with FPG. In fact, with this recommended 
cutoff point, A1C identified 33% less cases of undiagno-
sed diabetes than FPG ≥ 7.0 mmol/L (10). Therefore, 
an argument for population-specific A1C cutoff points 
emerged, especially among high risk populations.
Haitians are one of those high risk populations. 
According to the International Diabetes Federation, 
the prevalence of T2D in Haiti was 7.2% for 20 to 
79-year-olds in 2010 (11). Official data for Haitian-
-Americans (HA) are not available. A small sample (n 
= 51) collected in a Haitian community (Little Haiti) 
in the Miami-Dade County, FL, among Haitian immi-
grants estimated a 33% prevalence of diabetes (12). Sin-
ce acculturation may increase obesity rates in Haitian 
immigrants, prevalence of T2D is likely to be higher 
among them compared with Haitians living in Haiti. 
According to the US Census Bureau, there are 548,199 
Haitians living in the US, 30% of whom reside in the 
Miami-Dade and Broward Counties, FL, making them 
the second largest immigrant group (behind Cubans) 
in those counties (13).
The aims of this study were to evaluate the validity 
of A1C as a diagnostic tool for T2D, and to determine 
the most appropriate A1C cutoff point for T2D diag-
nosis in a sample of HA aged ≥ 35 years old, using the 
criteria of FPG ≥ 7.0 mmol/L as the cutoff point for 
diabetes diagnosis.
METHODS
Parent study
Participants
Our current study used male and female adults, ≥ 35 
years, who were not diagnosed with diabetes in the pa-
rent, case/control study of HA with T2D (n = 130), 
and without diabetes (n = 129). To be considered a 
HA, respondents needed to self-report having two pa-
rents born in Haiti. The candidates were screened by 
a trained interviewer, who was familiar with Haitian 
culture and who spoke English and Creole. Questions 
concerning length of stay in the United States and pla-
ce of birth were asked to candidates who qualified. The 
target population was recruited to achieve sufficient 
power (80%) to determine a medium effect (≥ 0.50) 
size in cardiovascular disease risk factors and to distin-
guish differences among 4 groups (gender and two age 
categories) for cases (with diabetes) and controls (wi-
thout diabetes). 
It was determined that 240 participants (30 partici-
pants per four groups with diabetes, n = 120, and wi-
thout diabetes, n = 120) would be sufficient, based on 
our previous studies in other populations and by using 
Cohen’s rule of thumb (n = 30 per group) (14). Since 
we anticipated cases of undiagnosed diabetes, the target 
sample size was increased to accommodate reclassifica-
tion and possible missing data. 
Data collection for the parent study
Recruitment was conducted by alternating between se-
lecting potential subjects with and then without T2D. 
Recruitment of HA participants (n = 259) was from 
community-based sources: (a) Local diabetes educators 
& community health practitioners in Miami-Dade and 
Broward Counties (several local diabetes educators who 
were either former students or in close contact with the 
Department of Dietetics and Nutrition at Florida Inter-
national University-FIU; official letters of invitation ou-
tlining the study mailed to the diabetes educators and 
health professionals in Miami-Dade and Broward county 
areas requesting their cooperation in recruiting indivi-
duals); (b) FIU faculty, staff and students (invitational 
flyers were distributed to all university faculty, staff and 
students using the university-wide e-mail system and ex-
plaining the research protocol and requesting their assis-
tance in the study); (c) Several residential rental facilities 
also agreed to help in the recruitment process; (d) Adver-
tisements (printed ads were placed in local Haitian news-
papers and principal gathering places of these groups, 
such as churches, supermarkets, and restaurants; radio 
advertisement on local Creole stations was also aired). 
When the recruitment target was reached (259, as 
explained in the “participants” section), all efforts to 
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recruit participants stopped. Interested participants 
were initially interviewed on the phone. At that mo-
ment, the study purpose was explained and the age and 
gender of the responders were determined. To ascer-
tain T2D status, each participant who self-reported ha-
ving diabetes was asked for age of diagnosis and initial 
treatment modalities. Exclusion criteria were belonging 
to any other ethnicity, age < 35 years old, pregnant or 
lactating women. If a subject was determined to be 
eligible, then his or her participation was requested at 
the Human Nutrition Laboratory at FIU. Participants 
were instructed to refrain from smoking, consuming 
any food or beverages except water, and engaging in 
any unusual exercise for at least eight hours prior to 
blood collection.
 This study was approved by the Institutional Re-
view Board at FIU. The purpose and protocol of the 
study were explained to the subjects, and their written 
consent, either in English or Creole, was obtained be-
fore the study began. Laboratory results showed that 
fifteen participants who reported not having diabetes 
were reclassified as having T2D according to FPG ≥ 
7.0 mmol/L. These participants were given their labo-
ratory results and referred to their physicians. 
Present study
For the present study data analysis, subjects who repor-
ted previous diagnosis of diabetes (n = 130) or were 
missing values for A1C (n = 1) were excluded. A to-
tal of 128 participants were included in the analysis of 
the data. Subjects who reported previous diagnosis of 
diabetes were excluded from our analysis because they 
were taking medication that decreased their FPG below 
the threshold of diagnosis, which is, in fact, the goal of 
the diabetes treatment.
Measures
Twenty mL of venous blood were collected from each 
subject after an overnight fast (at least 8 hours) by a 
certified phlebotomist using standard laboratory tech-
niques. Blood samples were collected in two tubes: a 
Vaccutainer Serum Separator Tube (SST) for analysis 
of glucose, and another tube containing ethylenedia-
mine tetra-acetic acid (EDTA) to analyze A1C. After 
complete coagulation (30-45 minutes), SST was centri-
fuged at 2,500 RPM for 30 minutes. Serum was trans-
ferred from SST into labeled plastic tubes for glucose 
analysis. Glucose levels were measured by hexokinase 
enzymatic methods. A1C percentages were measu-
red in whole blood with close tube sampling (CTS), 
in duplicate (CV < 1.7%), with the Roche Tina Quant 
Second Generation A1C (AC1-2) immunoassay me-
thod of Laboratory Corporation of America, Miami, 
FL (LabCorp®). The immunoassay method expresses 
A1C as a percent of total hemoglobin (Hb); whereas 
High Pressure Liquid Chromatography (HPLC) ex-
presses A1C as a percent of total HbA. Since amino 
acids substitution in HbS and HbC (the most common 
variants of A1C) are close to the glycated N-terminus, 
it is possible to overestimate A1C; however, several 
studies have found comparable results using standard 
techniques (15-17). The system used for our assays has 
matched the National Glycohaemoglobin Standardi-
zation Program (NGSP) against the Hb variants and 
has been certified to follow The Diabetes Control and 
Complications Trial (DCCT) (15,16). Moreover, our 
immunoassay method has been validated against boro-
nate-affinity HPLC in two groups of African American 
patients, one with hemoglobinopathy and another wi-
thout hemoglobinopathy, and whose A1C < 7.0% (17).
Statistical analysis
Data were divided into three categories according to 
the current ADA classification (6): normal FPG (< 5.6 
mmol/L), impaired fasting glucose (IFG) (5.6-6.9 
mmol/L), and undiagnosed diabetes (≥ 7.0 mmol/L). 
Percentages of subjects above A1C cutoff points 
among the three categories were compared using bar 
graphs. Mean A1C for subjects with normal FPG (< 
5.6 mmol/L) was computed. Sensitivity and specificity 
were evaluated at 1, 2, 3, and 4 standard deviations 
above this mean. Also, the cutoff point recommended 
by the ADA for diabetes diagnosis was plotted in the 
analysis (A1C ≥ 6.5%). The ADA criterion for diagno-
sing diabetes with FPG ≥ 7.0 mmol/L was considered 
the gold standard. 
Receiver operating characteristics (ROC) analysis 
was run in order to measure sensitivity and specificity 
of A1C in detecting diabetes at different cutoff points, 
and to determine the best predictive cutoff value (18). 
Sensitivity is the proportion of subjects at or above 
the A1C cutoff point who have diabetes (FPG ≥ 7.0 
mmol/L). Specificity is the proportion of individuals 
with A1C level below the cutoff point who do not have 
diabetes (FPG < 7.0 mmol/L). The ROC curve plots 
sensitivity versus 1 minus specificity at each cutoff level. 
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The greater the area under the curve (AUC), the better 
the prediction value of A1C for detecting diabetes. An 
AUC of 0.5 means no prediction value, whereas a value 
of 1.0 means perfect prediction value. Statistical analy-
sis was run using SPSS 18.0 (Chicago).
RESULTS
Participants were all born in Haiti and reported mi-
grating to the United States. There was no significant 
difference in the length of stay (less than 10 years) for 
those with undiagnosed diabetes compared with tho-
se without diabetes (20.0% and 30.9% respectively, P = 
0.550). The linear correlation between A1C and FPG 
was highly significant (P < 0.001), with a correlation 
coefficient of 0.75. Mean A1C for participants with 
normal FPG, IFG and diabetes were 5.8 ± 0.46%, 6.1 
± 0.47%, and 7.6 ± 1.75%, respectively (P < 0.001). No 
significant differences were found for age, gender, body 
mass index (BMI), and waist circumference among the 
three categories. These values were 52.5 ± 10.5 years, 
51% female, 28.6 ± 4.6 kg/m2, and 95.6 ± 12.1 cm for 
normal FPG (n = 75); 57.3 ± 10.6 years, 50% female, 
29.3 ± 5.7 kg/m2, and 96.8 ± 14.1 cm for IFG (n = 
38); 53.2 ± 13.5 years, 40% female, 30.1 ± 5.9 kg/m2, 
and 97.9 ± 11.6 cm for subjects with T2D (n = 15). 
Cutoff points were determined using mean A1C for 
participants with normal FPG and adding 1, 2, 3, and 
4 standard deviations. These points were 6.26%, 6.72%, 
7.18%, and 7.64% respectively. In addition, the cutoff 
point recommended by the ADA (A1C ≥ 6.5%) was 
also evaluated. Figure 1 shows the percentage of the 
population at or above specific cutoff values. Thirty-
-two percent of the population had A1C levels at or 
above 6.26% and 18.8% had A1C levels at or above 
6.50%. A total of 44.7% of subjects with IFG and 80% 
with undiagnosed diabetes were detected with an A1C 
cutoff point of 6.26%. Similarly, 18.4% of subjects with 
IFG and 73.3% of participants with undiagnosed dia-
betes were detected with an A1C cutoff point of 6.50% 
(recommended by the ADA). 
In this specific population, A1C showed a high pre-
dictive value for detecting undiagnosed diabetes. The 
area under the ROC curve was 0.86 (Figure 2). In 
addition, an A1C cutoff point of 6.26% had sensitivity 
of 80% and specificity of 74%, whereas an A1C cutoff 
point of 6.50% had sensitivity of 73% and specificity of 
89%. Sensitivity decreased as specificity increased with 
every increasing cutoff value (Table 1). 
Table 1. Sensitivity and specificity of A1C for detecting undiagnosed 
diabetes in Haitian-Americans (fasting plasma glucose ≥ 7.0 mmol/L) at 
increasing A1C cutoff points
A1C cutoff (%) Sensitivity Specificity
6.26 80 74
6.50 73 89
6.72 60 97
7.18 47 100
7.64 33 100
Data are %. Sensitivity: 100 X TP/(TP + FN). Specificity: 100 X TN/(TN + FP).
TP: true positive (above the cutoff level for A1C and FPG ≥ 7.0 mmol/L); FN: false negative 
(below the cutoff level for A1C and FPG ≥ 7.0 mmol/L); TN: true negative (below the cutoff level 
for A1C and FPG < 7.0 mmol/L); FP: false positive (above the cutoff level for A1C and FPG < 
7.0 mmol/L).
Figure 1. Percentage of Haitian-Americans aged ≥ 35 years old at 
different A1C cutoff points.
Figure 2. Continuous line: ROC curve for A1C as a diagnostic indicator for 
diabetes (fasting plasma glucose ≥ 7.0 mmol/L). Dotted line: Diagonal 
indicating area under the curve = 0.50. 
DISCUSSION
The ADA has adopted A1C as a valid diagnostic tool for 
diabetes on the basis that the test is now standardized, 
does not require fasting, has less intra-individual varia-
bility than FPG, and is not affected by stress or illness. 
Hemoglobin A1C in diagnosis for Haitians
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The recommended cutoff value for diabetes diagnosis 
has been set at A1C ≥ 6.5% (6). In a recent study using 
data from the National Health and Nutrition Exami-
nation Survey (NHANES), A1C ≥ 6.5% detected only 
30% of the subjects with undiagnosed diabetes. In addi-
tion, 19% of subjects with undiagnosed diabetes were 
detected by both FPG and OGTT, but not by A1C. Si-
milarly, 1% of the population previously diagnosed with 
diabetes, but who has not taken medication yet, was 
not detected by A1C (10). These results from a sample 
representative of the national US population demons-
trate that the arbitrary cutoff point of 6.5% should be 
considered with caution.
Studies from several countries have documented 
that different ethnicities have different A1C values (1-
4,8). High sensitivity is important for minorities, even 
at the expense of lower specificity, in order for cases to 
be discovered. In the US, the Diabetes Prevention Pro-
gram has shown that African Americans and Hispanics 
with impaired glucose tolerance (IGT) had higher A1C 
values compared with non-Hispanic Whites with IGT, 
even after adjusting for confounding variables. This fin-
ding may be explained by other factors that are not re-
lated to glucose control such as hemoglobin glycation 
rate or red blood cell survival time (9). 
In our sample, mean A1C for subjects with normal 
FPG (FPG < 5.6 mmol/L) was 5.8% ± 0.46%, which is 
higher compared with other populations. For instance, 
in data obtained from the NHANES III, mean for sub-
jects with normal FPG was 5.17% ± 0.45% (19). The 
difference is even greater if we take into consideration 
that, in this study, normal FPG was defined as FPG < 
6.1 mmol/L, which may have increased mean A1C 
compared with a cutoff of FPG < 5.6 mmol/L. Means 
for the US population without diabetes are usual ly hi-
gher because they include people with normal and high 
FPG. However, they are still lower than that found in 
our sample for subjects with normal FPG. For instan-
ce, the overall mean A1C found in the NHANES for 
non-Hispanic Whites, non-Hispanic Blacks and Mexi-
can Americans without diabetes were 5.3 ± 0.01, 5.4 ± 
0.01, and 5.4 ± 0.01%, respectively (20). From these 
results, it is inferred that even in the presence of nor-
mal FPG, A1C levels were elevated in our sample of 
HA compared with the US population without dia-
betes. Furthermore, 32% of HA without diabetes had 
A1C levels greater than 6.26%. In the NHANES, only 
2.9% of the US population without diabetes had A1C 
greater than 6.1% (20). Therefore, in this particular 
sample, there is a considerable proportion of HA with 
high A1C compared with the general US population 
without diabetes.
In our sample, A1C showed high predictive value in 
detecting undiagnosed T2D (AUC = 0.86). However, 
our optimal cutoff point differs from the one suggested 
by the ADA. Since the mean for normal subjects ± 1SD 
is considered normal range in any test (5.8 ± 0.46% in 
our sample), any value that is above the normal range 
should be considered abnormal (> 6.26% for our sam-
ple). This is further confirmed by the ROC analysis. 
Using an A1C cutoff point of 6.26% (1 SD above the 
mean for participants with normal FPG) we had 80% 
sensitivity and 74% specificity. Applying the A1C cutoff 
point of 6.5% adopted by the ADA, we had 73% sensiti-
vity and 89% specificity. The cutoff point recommended 
by the ADA had lower sensitivity but higher specificity. 
This issue was addressed by the International Expert 
Committee who recommended the cutoff point (5). 
The argument was that specificity is more important 
than sensitivity because diagnosing subjects as positive 
when in fact, they are not, will be costly for the health 
system. While this may be true for the general popu-
lation, in minorities like HA with a high prevalence of 
T2D and a high rate of poverty, the cost of complica-
tions caused by undiagnosed diabetes may offset the 
cost related to false positives.
This is further confirmed by studies in different 
high risk populations around the world that suggest ei-
ther ≥ 6.1% or ≥ 6.2% as the optimum cutoff point for 
diabetes diagnosis (1-4,21-23) and by the low sensitivi-
ty found for A1C when the recommended cutoff point 
was applied to general US population (10). It should 
also be noted that 44.7% of the participants with IFG 
were detected by the 6.26% cutoff point, which indica-
tes that a much lower cutoff value should be used for 
that purpose in this particular sample. 
One reason for the lack of consensus for routine 
diabetes screening may be the lack of diagnostic ac-
curacy of A1C in earlier studies. Now that technology 
has improved, evidence for A1C as a diagnostic tool for 
minorities and hard-to-reach population may be built. 
Once the barrier of 8-hour fasting is removed for these 
groups, early diagnosis and lifestyle management would 
have the potential to reduce diabetes-related compli-
cations. The predictive validity of A1C as a diagnostic 
tool (compared with FPG) was found to vary by risk 
factor score categories (low, moderate, and high preva-
lence) in a nationally representative sample (24). The 
Hemoglobin A1C in diagnosis for Haitians
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investigators found that intermediate A1C (5.5%-6.0%) 
could exclude diabetes for persons in the moderate, but 
not in the high risk groups (24). Since minorities such 
as HA are at high risk for diabetes, lower A1C cutoffs 
would increase sensitivity at the expense of lower speci-
ficity. The fact that A1C levels indicating high glycemia 
are positively correlated with microvascular complica-
tions (24) offsets the expense of false diagnoses. 
The new diagnostic criterion will have important 
public health implications for high risk populations. Ac-
cording to our data, a considerable proportion of HA 
in our sample will be missed by the established cutoff 
point and will be left without treatment. It is imperative 
to have defined specific cutoff points, to explain why 
HA in our sample have high A1C even in the presence 
of normal FPG, and to examine how the rates of com-
plications are related to A1C levels in this population. 
The prevalence of undiagnosed diabetes was 11.7% 
(15/128) in this study. Several limitations need to be 
noted. Our sample may not represent the HA popula-
tion in Miami-Dade County due to the small sample 
size and selection bias. HA who were willing to parti-
cipate in a study that involved revealing social informa-
tion and drawing blood may have different risk factors 
compared with those HA who were asked to participa-
te, but refused. Although community leaders generally 
have access to hard-to-reach HA, they may have selecti-
vely approached HA with more cooperative social cha-
racteristics. Another limitation of this study was that 
data was taken in a single time-point. As such, temporal 
changes in Miami-Dade County were not taken into 
account. 
Technical limitations existed, as well. Although FPG 
is the gold standard, the ADA recommends that two 
tests are used for accuracy, and only one measure was 
taken in this study. Regarding interference of hemo-
globin variants, the most common variant for our po-
pulation would be the HbC or the HbS trait, if HA 
were sampled in the “Black, non-Hispanic” category 
(25). The National Diabetes Clearinghouse (NIDC) 
estimates 8% of African Americans have the HbS trait 
and 2.3% have the HbC trait (26). Even though the 
immunoassay method used to assess A1C was validated 
against ion-exchange HPLC, HbS or HbC are close to 
the glycated N-terminus and interference resulting in 
higher readings cannot be completely ruled out (17). 
However, interference of the HbS or HbC traits are 
most likely to be found at the extremely high A1C va-
lues (17).
Relative contributions of fasting and postprandial 
hyperglycemia were found to vary across A1C quintiles 
in a study by Monnier and cols. (27). However, fasting 
hyperglycemia was critical for A1C values above 8.4%, 
since postprandial exposure remains stable in the three 
upper quintiles (27). Three categories were compared 
in our analysis: normal, IFG, and undiagnosed T2D 
using FPG. As A1C values were also from fasting blood 
samples, postprandial glucose levels would not be an 
issue in the determination of cutoff points.
A1C may be useful in detecting diabetes in com-
munity settings among HA. A positive test should be 
confirmed by fasting plasma glucose or a second A1C 
reading. However, our study with only one A1C and 
FPG reading mimics a common decision-making prac-
tice for diabetes diagnosis among this particular hard-
-to-reach population.
In our study, A1C showed a high predictive value 
for detecting undiagnosed diabetes in HA. A cutoff 
point of 6.26% (1 SD above the mean for subjects with 
normal FPG) was the optimum value to detect undiag-
nosed T2D in this particular sample. Larger cross-sec-
tional and prospective longitudinal studies are needed 
to confirm these results.
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